Research Topics
| R Schennach-WolffSummaryAffiliation: University of Munich Country: Germany Publications
| Collaborators
|
Detail Information
Publications
Remission and recovery and their predictors in schizophrenia spectrum disorder: results from a 1-year follow-up naturalistic trialRebecca Schennach
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336, Munich, Germany
Psychiatr Q 83:187-207. 2012..0113) were found to be significantly predictive of recovery. Our results underline the need to implement more specific treatment strategies to improve long-term outcome...
Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorderRebecca Schennach-Wolff
Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, 80336 Munich, Germany
J Psychiatr Res 45:1639-47. 2011..To examine the influencing factors and predictors of early improvement in schizophrenia patients...
Is the PANSS used correctly? a systematic reviewMichael Obermeier
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, Munich, Germany
BMC Psychiatry 11:113. 2011..ratio scale) leads to a set of mathematical problems, potentially resulting in erroneous results concerning the efficacy of the treatment...
Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?Rebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Eur Neuropsychopharmacol 21:370-8. 2011..To evaluate the predictive validity of early response compared to other well-known predictor variables in acutely ill first-episode patients...
Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population? Results of a CGI and PANSS linking analysis in a naturalistic studyRebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Munich, Germany
J Clin Psychopharmacol 30:726-31. 2010..Furthermore, these linking results were compared with those derived from randomized controlled trials to examine if the baseline severity might influence the linking results...
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression ScaleR Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Acta Psychiatr Scand 123:228-38. 2011..To examine depressive symptoms, their course during treatment, and influence on outcome...
A critical analysis and discussion of the appropriateness of the schizophrenia consensus remission criteria in clinical pharmaceutical trialsR Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Pharmacopsychiatry 43:245-51. 2010..The aim of this paper is to apply the proposed consensus remission criteria to an acutely ill inpatient sample at admission and evaluate their adaptability in this patient population and pharmaceutical trials...
An early improvement threshold to predict response and remission in first-episode schizophreniaRebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Nussbaumstrasse 7, Muenchen 80336, Germany
Br J Psychiatry 196:460-6. 2010..Early improvement with treatment is thought to be important in patients with first-episode schizophrenia, yet a valid definition is still outstanding...
Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disordersR Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
Eur Psychiatry 26:284-92. 2011..Purpose of this study was to assess subjective well-being in schizophrenia inpatients and to find variables predictive for response and remission of subjective well-being...
Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?Rebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
World J Biol Psychiatry 11:729-38. 2010..To examine quality of life and subjective well-being as predictors of symptomatic treatment outcome...
Attitude towards adherence in patients with schizophrenia at dischargeRebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Nussbaumstr 7, 80336 Munich, Germany
J Psychiatr Res 43:1294-301. 2009....
Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disordersRebecca Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Schizophr Res 113:210-7. 2009..To assess criteria and to identify predictive factors for functional outcome. The criteria should cover all domains proposed by the Remission in Schizophrenia Working Group...
Outcome of suicidal patients with schizophrenia: results from a naturalistic studyR Schennach-Wolff
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Acta Psychiatr Scand 121:359-70. 2010..Purpose was to assess suicidality before and at the time of admission in patients with schizophrenia and compare outcome differences...
Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patientsM Jager
Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, D 80336 Munich, Germany
Schizophr Res 118:183-8. 2010..To describe the course of positive and negative symptoms during inpatient treatment and examine remission and response rates under routine clinical care conditions...
Effect of aripiprazole on cognition in the treatment of patients with schizophreniaM Riedel
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University, Munich, Germany
Pharmacopsychiatry 43:50-7. 2010..The aim of this study was to assess the cognitive effects of aripiprazole in inpatients with schizophrenia...
The validity of self-rated psychotic symptoms in depressed inpatientsF Seemüller
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
Eur Psychiatry 27:547-52. 2012..Self-ratings of psychotic experiences might be biased by depressive symptoms...
The RSM-scale: a pilot study on a new specific scale for self- and observer-rated quality of life in patients with schizophreniaM Riedel
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstr 7, 80336, Munich, Germany
Qual Life Res 20:263-72. 2011..To develop and evaluate a self- and observer-rating scale on quality of life in patients suffering from schizophrenia with regard to the efficacy of atypical antipsychotics based on different dimensions and to apply within a pilot study...
Neurocognition and its influencing factors in the treatment of schizophrenia-effects of aripiprazole, olanzapine, quetiapine and risperidoneM Riedel
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Munich, Germany
Hum Psychopharmacol 25:116-25. 2010..To examine influencing variables of neurocognition in patients with schizophrenia and to predict cognition during antipsychotic treatment...
[Bipolar depression. Spectrum of clinical pictures and differentiation from unipolar depression]F Seemüller
Klinik fur Psychiatrie und Psychotherapie, LMU Munchen, Nussbaumstrasse 7, 80336, Munchen, Deutschland
Nervenarzt 81:531-8. 2010..Therefore we propose to assess the risk of each patient for having bipolar disorder individually. Patients who are at a high risk should at least be informed and should be closely monitored for the development of manic episodes...
Safety evaluation of zotepine for the treatment of schizophreniaMichael Riedel
Ludwig Maximilians University Munich, Department of Psychiatry and Psychotherapy, Munich, Germany
Expert Opin Drug Saf 9:659-66. 2010..Zotepine is an antipsychotic with atypical properties and previous data have suggested a very favorable side effect profile...
Does early improvement in major depression protect against treatment emergent suicidal ideation?Florian Seemüller
Department of Psychiatry, Ludwig Maximilians University, Nussbaumstr 7, Munich, Germany
J Affect Disord 124:183-6. 2010..To investigate the association of early improvement and treatment emergent suicidal ideation in a large sample (N=705) of naturalistically treated inpatients with major depressive disorder...
Should the PANSS be rescaled?Michael Obermeier
Department of Psychiatry and Psychotherapy, Ludwig Maximilians University Munich, Nussbaumstrasse 7, 80336 Munich, Germany
Schizophr Bull 36:455-60. 2010..Even significance levels of estimated treatment effects change, depending on the structure of the data (eg, baseline symptom severity). Using a PANSS version with items ranging from 0 to 6 would avoid such often neglected pitfalls...
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentNorbert Muller
Department of Psychiatry and Psychotherapy, Ludwig Maximilians Universitat Munchen, Germany
Schizophr Res 121:118-24. 2010..In future, further trials are needed to investigate the effect of COX-2 inhibitors on prodromal and negative symptoms of schizophrenia...
Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trialsFlorian Seemüller
Department of Psychiatry and Psychotherapy, Ludwig Maximilian University Munich, Munich, Germany
J Clin Psychiatry 71:1425-33. 2010..Because of strict inclusion and exclusion criteria, results drawn from placebo-controlled randomized antidepressant efficacy trials may not be transferable to real-world patients...
